Physician profile
Rex H Wu
NPI 1861456196
$6,976.04
in general payments reported to CMS, 2019-2025
18 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $1,738 · 2021: $1,531 · 2022: $328 · 2023: $620 · 2024: $524 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,229.87 | 2019-2025 | Vemlidy |
| Madrigal Pharmaceuticals | $573.15 | 2024-2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $520.51 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $308.54 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $263.05 | 2019-2023 | Rinvoq |
| Janssen Pharmaceuticals, INC | $176.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $169.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Angiodynamics, INC. | $135.48 | 2024 | Angiodynamics |
| Idorsia Pharmaceuticals US INC | $115.46 | 2023 | Quviviq |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Amgen INC. | $103.83 | 2019-2024 | Repatha, Krystexxa |
| Seqirus USA INC | $49.75 | 2019-2025 | Fluad, Fluad Quadrivalent, Flucelvax Quadrivalent |
| Amarin Pharma, INC. | $19.32 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.83 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.35 | 2022 | |
| Merck Sharp & Dohme LLC | $12.06 | 2019 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.